NVO Stock Recent News

CNBC's Karen Gilchrist discusses the impact of U.S. compounded weight loss drugs and potential tariffs on obesity drug giant Novo Nordisk.

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment. "I'm very confident about CagriSema," he told shareholders at the firm's Annual General Meeting in Copenhagen, Denmark.

PERTH, Australia, March 28, 2025 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) advises that as of Monday, 31 March 2025, Novo has changed its provider for shareholder registry services from MUFG Pension & Market Services to Automic Pty Ltd.

Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday.

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its 2025 guidance in its quarterly results.

JP Morgan expects Novo Nordisk (NYSE:NVO) to hold the line on its 2025 growth targets when it reports first-quarter results, saying a reaffirmation of guidance would help calm nerves after a sluggish start to the year for weight-loss drug Wegovy in the US. Analyst Richard Vosser forecasts sales of DKr77.1bn, around 4% below Bloomberg consensus estimates, largely due to lower expectations for both Wegovy and diabetes treatment Ozempic.

Lexicon Pharmaceuticals said on Friday it has entered into an agreement with Novo Nordisk to license its non-incretin-based experimental obesity drug for up to $1 billion.

Novo Nordisk's (NVO -2.13%) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt like the company ingested some of its own treatment.

Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting Wegovy sales. CEO Lars Fruergaard Jørgensen told shareholders at its Annual General Meeting that it was pursuing legal action against companies it believes to be violating its intellectual property.

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. Eli Lilly.